Two-year observation of the clinical efficacy in treating chronic hepatitis B Patients with Ganxian recipe and lamivudine.
OBJECTIVE
To evaluate the clinical efficacy of Ganxian recipe (GXR) and lamivudine (LVD) in a two-year treatment of chronic hepatitis B (CHB).


METHODS
One hundred and twenty patients with CHB were randomly divided into the combinedly treated group (combined group) of 40 CHB patients who were treated with GXR combined with LVD. Another 40 CHB patients were treated with LVD alone (WM group), and still another 40 CHB patients were treated with GXR alone (TCM group). All these cases were randomly controlled and observed for two years.


RESULTS
Comprehensive efficacy: Total effective rate of the combined group (complete response and partial response) was 92.5%, while that of the WM group was 67.5% and TCM group 57.5%, respectively, with the difference between them was significant (P < 0.01); after treatment, the hepatic functions (AST, ALT, SB) of the three groups were all reduced, and the reduction in the combined group was particularly significant in comparison with the WM group or TCM group, P < 0.05 or P < 0.01 respectively, suggesting that the effect in the combined group was better than that in the other two groups; the rate of tyrosine-methionine-aspartate-aspartate (YMDD) virus mutation: it was 7.5% in the combined group, 40.0% in the WM group, and 5.0% in the TCM group; liver fibrosis improvement parameter: after treatment, the results in the combined group got better than those in the other two groups.


CONCLUSIONS
GXR could inhibit the appearance of YMDD after long-term application of LVD, and combined use has marked synergism.
Shen
Wei-sheng
WS
Jiangyin Hospital Affiliated to Medical College of South Eastern University, Jiangsu, China. sws6275171@vip.sina.com
Yang
Hong-zhi
HZ
Hong
Qi
Q
Zhang
Yong-qiang
YQ
Xie
He-ping
HP
Bian
Zhuang
Z
D000293:Adolescent; D000328:Adult; D005260:Female; D005787:Gene Frequency; D005814:Genes, Viral; D006510:Hepatitis B Antibodies / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood / Q000276:immunology; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000150:complications / Q000503:physiopathology / Q000628:therapy* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects / Q000627:therapeutic use*; D008099:Liver / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000473:pathology / Q000821:virology; D008297:Male; D008516:Medicine, Chinese Traditional / Q000379:methods; D008875:Middle Aged; D009154:Mutation; D008517:Phytotherapy / Q000009:adverse effects; D028321:Plant Preparations / Q000009:adverse effects / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D006510:Hepatitis B Antibodies; D006513:Hepatitis B e Antigens; D028321:Plant Preparations; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine